Davide Dazzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6793491/publications.pdf

Version: 2024-02-01

304743 395702 3,055 33 22 33 citations h-index g-index papers 33 33 33 2492 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Quantification of Global Ocular Motility Impairment in Graves' Orbitopathy by Measuring Eye Muscle Ductions. Thyroid, 2021, 31, 280-287.	4.5	5
2	SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes and Endocrinology, the, 2020, 8, 739-741.	11.4	225
3	Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study. Thyroid, 2019, 29, 1828-1833.	4.5	22
4	Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. BMC Nephrology, 2018, 19, 347.	1.8	2
5	Retinal Photoreceptor Functions Are Compromised in Patients With Resistance to Thyroid Hormone Syndrome (RTH \hat{I}^2). Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2620-2627.	3.6	20
6	Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 422-431.	3.6	291
7	The therapeutic outcome of intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology, 2014, 170, 55-61.	3.7	39
8	Therapeutic Outcomes of High-Dose Intravenous Steroids in the Treatment of Dysthyroid Optic Neuropathy. Thyroid, 2014, 24, 897-905.	4.5	94
9	A Quantitative Method for Assessing the Degree of Axial Proptosis in Relation to Orbital Tissue Involvement in Graves' Orbitopathy. Ophthalmology, 2013, 120, 1092-1098.	5. 2	14
10	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. JAMA Ophthalmology, 2012, 130, 122.	2.4	75
11	Serum BAFF Concentrations in Patients with Graves' Disease and Orbitopathy before and after Immunosuppressive Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E755-E759.	3.6	39
12	Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 905-913.	3.6	95
13	Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions. Clinical and Experimental Immunology, 2010, 161, 436-443.	2.6	49
14	Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. European Journal of Endocrinology, 2010, 162, 145-151.	3.7	106
15	Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers â‰⊉ cm. Endocrine-Related Cancer, 2009, 16, 201-210.	3.1	50
16	Graves' Orbitopathy Activation after Radioactive Iodine Therapy with and without Steroid Prophylaxis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3381-3386.	3.6	82
17	Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltrates. Clinical Immunology, 2009, 131, 360-365.	3.2	58
18	<i>RET</i> genotypes in sporadic medullary thyroid cancer: studies in a large Italian series. Clinical Endocrinology, 2008, 69, 418-425.	2.4	36

#	Article	IF	Citations
19	Side Effects of Anabolic Androgenic Steroids Abuse. International Journal of Sports Medicine, 2008, 29, 679-687.	1.7	96
20	Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. European Journal of Endocrinology, 2007, 156, 33-40.	3.7	230
21	The Influence of Selenium Supplementation on Postpartum Thyroid Status in Pregnant Women with Thyroid Peroxidase Autoantibodies. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1263-1268.	3.6	310
22	Euthyroid women with autoimmune disease undergoing assisted reproduction technologies: The role of autoimmunity and thyroid function. Journal of Endocrinological Investigation, 2007, 30, 3-8.	3.3	99
23	Levothyroxine Treatment in Euthyroid Pregnant Women with Autoimmune Thyroid Disease: Effects on Obstetrical Complications. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2587-2591.	3.6	647
24	Radioiodine treatment of non-toxic multinodular goitre: effects of combination with lithium. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1081-1088.	6.4	13
25	Levothyroxine treatment in thyroid peroxidase antibody-positive women undergoing assisted reproduction technologies: a prospective study. Human Reproduction, 2005, 20, 1529-1533.	0.9	193
26	Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Research and Clinical Practice, 2005, 70, 20-25.	2.8	46
27	Prediction of the Progression of Thyroid-Associated Ophthalmopathy at First Ophthalmologic Examination: Use of a Neural Network. Thyroid, 2002, 12, 233-236.	4.5	6
28	Classification and prediction of the progression of thyroid-associated ophthalmopathy by an artificial neural network. Ophthalmology, 2002, 109, 1703-1708.	5.2	29
29	The control of blood glucose in the critical diabetic patient. Journal of Diabetes and Its Complications, 2001, 15, 80-87.	2.3	55
30	The management of thyroid disease by GPs. Family Practice, 2001, 18, 195-198.	1.9	2
31	What Do the People Think (and Know) About Informed Consent for Participation in a Medical Trial. Archives of Internal Medicine, 2001, 161, 768-769.	3.8	9
32	Effects of alcohol consumption and accompanying diet on metabolic response to arginine in chronic alcoholics Journal of Studies on Alcohol and Drugs, 1999, 60, 581-585.	2.3	1
33	Effects of maternal weight variations and gestational diabetes mellitus on neonatal birth weight. Journal of Diabetes and Its Complications, 1996, 10, 78-83.	2.3	17